Very often truths and facts are not fungible and we must respect that. Truth is not a distraction. Truth is the foundation of a functional civilization. We cannot sacrifice the truth to find common grounds.

Our lab at Yale U/Wu Tsai Institute has a postdoctoral position on neurodegeneration, neuro-glial-vascular biology using 2photon, calcium/voltage imaging, gene editing,transcriptome/proteome, 3D EM, translational neurosci/chemistry. Email me if interested #postdoctoral . RT pls

Congratulations to Charles Piller for yet another award on his careful and courageous reporting re: scientific misconduct in neuroscience. We have important work to do rebuild a culture of integrity. Key leaders in this effort include Mu Yang, Ph.D. Cheshire Elisabeth Bik.

Never before had the American Academy of Neurology advertised a drug in its annual Congress. The first #AANAM plenary started with a 5-minute video on how to deliver lecanemab to patients with #Alzheimers . As American Academy of Neurology I feel betrayed. The AAN sold some of its soul today.

Last week Vanderbilt Neurology hosted the 26th Annual Stroke Symposium. I learned so much from changes in CRAO management to ICH surgical treatments. Looking forward to next year already! Here are some highlights : Matthew Schrag Anne Hege Aamodt

Want to change the system? Post preprints and only post preprints - don't submit to journals, don't subscribe to journals, don't read journals - only hire and fund people based on their preprints.

Next up ➡️ Dr. Timothy Hohman is presenting on multi-omic signatures of #Alzheimers disease + sharing the impressive work + data resources coming out of the Alzheimer’s Disease Sequencing Project. @VUMCNeurology #VUMCNeurology #VandyADday

This photo was taken, during the recent 26th annual Vanderbilt Neurology Stroke and Neuroscience Symposium, of Dr. Matthew Schrag & me discussing the 'Patient Experience'.

Neurology's most enduring, always shattered dream: diverging slopes between treatments within the window of trials predict greater effects beyond them.
(1/5) Donepezil: had it not been for the washout period, this 24-week trial seemed disease-modifying.
neurology.org/doi/10.1212/wn…

Kasper Planeta Kepp Andrew Gregory The Guardian Matthew Schrag Lon S. Schneider, MD Robert Howard Madhav Thambisetty Karl Herrup A suggested revision to the The Guardian headline: 'Hundreds of thousands of dementia patients in England are protected from devastating new drugs thanks to the dispassionate review of clinical trial data by the NHS. The US FDA system lags behind'.

Check this out from Rebecca Embalabala. Vanderbilt Neurology Vanderbilt University Medical Center